Evaxion A/S (NASDAQ:EVAX) Now Covered by Analysts at JonesTrading

JonesTrading began coverage on shares of Evaxion A/S (NASDAQ:EVAX) in a report released on Tuesday morning,Benzinga reports. The firm issued a buy rating and a $10.00 target price on the stock.

EVAX has been the topic of several other reports. Lake Street Capital lowered their target price on shares of Evaxion A/S from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Evaxion A/S in a report on Friday, January 9th. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Evaxion A/S in a report on Monday. Finally, Maxim Group started coverage on shares of Evaxion A/S in a research report on Thursday, February 19th. They set a “buy” rating and a $10.00 target price for the company. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $11.00.

Evaxion A/S Stock Performance

EVAX stock opened at $3.58 on Tuesday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 5.85 and a current ratio of 5.85. Evaxion A/S has a 52 week low of $1.20 and a 52 week high of $12.15. The firm has a 50 day simple moving average of $3.84 and a 200 day simple moving average of $4.63. The stock has a market cap of $29.86 million, a P/E ratio of -2.71 and a beta of 0.28.

Evaxion A/S (NASDAQ:EVAX) last announced its quarterly earnings results on Thursday, March 5th. The company reported $0.30 earnings per share (EPS) for the quarter. Research analysts anticipate that Evaxion A/S will post -0.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in EVAX. SmartHarvest Portfolios LLC acquired a new position in shares of Evaxion A/S in the 4th quarter valued at $72,000. Northwestern Mutual Wealth Management Co. bought a new position in Evaxion A/S during the fourth quarter worth about $38,000. Finally, Wesbanco Bank Inc. bought a new position in Evaxion A/S during the fourth quarter worth about $48,000. Institutional investors own 11.04% of the company’s stock.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.